var data={"title":"Pneumococcal conjugate vaccine (10-valent) (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pneumococcal conjugate vaccine (10-valent) (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/492170?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739550\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Synflorix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739552\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739609\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> IM: <i>Infants 6 weeks to 6 months:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Healthy infants or those at high risk for invasive pneumococcal disease (eg, HIV, sickle cell disease): </i>Three-dose primary series: 0.5 mL/dose for 3 doses, followed by a booster dose of 0.5 mL (for a total of 4 doses). The first dose may be given as young as 6 weeks of age, but is typically given at 2 months of age. The second and third doses should be administered at 4 and 6 months of age. The booster dose may be given as young as 9 months of age but is typically administered at 12 to 15 months; allow a minimum interval of 1 month between each of the first 3 doses, and 6 months between dose 3 and the booster dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Healthy infants: </i>Alternatively, healthy infants 2 to 6 months may receive a two-dose primary series: 0.5 mL/dose for 2 doses, followed by a booster dose of 0.5 mL (for a total of 3 doses). The first dose may be given as young as 6 weeks of age, but is typically given at 2 months of age. The second dose should be administered at 4 months of age. The booster dose may be given as young as 9 months of age but is typically administered at 11 to 12 months; allow a minimum interval of 2 months between doses 1 and 2, and 6 months between doses 2 and the booster dose. <b>Note:</b> May not provide optimal protection particularly in infants at high risk for pneumococcal disease (eg, asplenia, sickle-cell disease, immunosuppressed).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Previously unvaccinated Older Infants and Children:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants 7 to 11 months:</i> 0.5 mL/dose for a total of 3 doses; 2 doses administered at least 1 month apart, followed by a third dose administered after 1 year of age, separated from the second dose by at least 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children 12 to 23 months:</i> 0.5 mL/dose for a total of 2 doses, administered at least 2 months apart. <b>Note:</b> Two-dose regimen in children 12 to 23 months of age at high risk for pneumococcal disease (eg, asplenia, sickle-cell disease, immunosuppressed) may not provide optimal protection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Healthy children &ge;24 months to &lt;6 years:</i> 0.5 mL/dose for a total of 2 doses, administered at least 2 months apart</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22457653\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22457654\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739639\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synflorix: 1 mcg of each capsular saccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3 mcg each of serotypes 4, 18C, and 19F (bound to protein D [from nontypeable <i>H. Influenzae</i>], tetanus toxoid, or diphtheria toxoid) per 0.5 mL (0.5 mL) [contains aluminum, natural rubber/natural latex in packaging]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739638\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739633\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intramuscular (IM): Shake well before use. Administer by IM injection only, preferably into the anterolateral aspect of the thigh in infants and into the deltoid in children. Do <b>not</b> administer intravenously or intradermally. Subcutaneous administration has not been studied. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Rule out bleeding disorders in patients &lt;2 years of age prior to immunization. NACI recommends that patients with bleeding disorders receive all routine recommended vaccinations according to schedule. Bleeding disorders should be corrected prior to immunization (when possible) or immunization should be scheduled shortly after antihemophilia or other similar therapy. In patients with bleeding disorder that cannot be corrected, IM gluteal injections should be avoided (if possible). When immunizing patients with bleeding disorders, a fine-gauge needle of the appropriate length can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 5 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy (eg, aspirin, warfarin, heparin) may be immunized via intramuscular injection without discontinuation of their anticoagulant therapy (NACI 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739554\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumococcal disease prevention: </b>Immunization of infants &ge; 6 weeks and children through 5 years against <i>Streptococcus pneumoniae</i> invasive diseases, pneumonia, and acute otitis media caused by serotypes included in the vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739549\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Synflorix may be confused with Synagis</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pneumococcal 10-Valent Conjugate Vaccine (Synflorix) may be confused with Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13) and Pneumococcal 23-Valent Polysaccharide Vaccine (Pneumo 23, Pneumovax 23)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pneu-C-10 (pneumococcal 10-valent conjugate vaccine) may be confused with Pneumo-C-13 (pneumococcal 13-valent conjugate vaccine) and Pneu-P-23 (pneumococcal 23-valent polysaccharide vaccine)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739579\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (32% to 66%), drowsiness (33% to 58%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (17% to 31%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (23% to 57%), erythema at injection site (children: 24% to 55%) swelling at injection site (16% to 44%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (rectal; &ge;38&deg; C: 26% to 37%; &gt;39&deg; C: 1% to 7%; &gt;40&deg; C: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Local: Induration at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Allergic dermatitis, anaphylaxis, angioedema, apnea (in premature infants &le;28 weeks' gestation), atopic dermatitis, bleeding at injection site, crying (abnormal), diarrhea, eczema, headache, hematoma at injection site, hypersensitivity reaction, hypotonic/hyporesponsive episode, injection site nodule, injection site pruritus, Kawasaki syndrome, nausea, seizure (febrile and nonfebrile), skin rash, swelling of injected limb (may involve adjacent joint), urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739557\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739558\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults but may occur in children and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from intramuscular (IM) administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pneumococcal infections: Not to be used to treat pneumococcal infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the Canadian National Advisory Committee on Immunization (NACI) recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (NACI 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Safety and efficacy have been established in infants and children &lt;2 years of age with HIV infection or sickle cell disease and at increased risk for pneumococcal infection. Safety and efficacy in other immunocompromised children at increased risk for pneumococcal infection (eg, splenic dysfunction, malignancy, nephrotic syndrome) has not been established. Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy, or other immunosuppressive therapy including high dose corticosteroids); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has occurred following IM vaccine administration in some premature infants; consider clinical status implications. Infants born &le;28 weeks' gestation, particularly those with a prior history of respiratory immaturity, may require respiratory function monitoring for 2 to 3 days after administration. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Routine immunization: Antibody response is provided only against pneumococcal serotypes included in the vaccine. Antibody response may also be observed to diphtheria toxoid, tetanus toxoid, and protein D (derived from nontypeable <i>Haemophilus influenzae</i>); however, recommended routine administration schedules for diphtheria, tetanus, or <i>H. influenzae</i> type b vaccines should still be followed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13769083\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13769081\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17136&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739555\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]). This product is indicated for use in infants and children.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739556\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739637\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Consider respiratory monitoring for 48 to 72 hours in premature infants (born &le;28 weeks gestation) due to risk of apnea. Monitor for for anaphylaxis and syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13739599\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes active immunization against invasive disease caused by <i>S. pneumoniae</i> capsular serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, all which are individually conjugated to a carrier protein (protein D, tetanus toxoid, or diphtheria toxoid); the aluminum salt, a mineral adjuvant, enhances the antibody response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671812\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Synflorix (AE, AR, AT, AU, BE, CL, CR, CY, CZ, DE, DK, DO, EC, EE, ES, GB, GT, HK, HN, HR, HU, ID, IE, IL, IS, JP, KR, KW, LB, LK, LT, LV, MT, MY, NI, NL, NZ, PA, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Canadian Immunization Guide, Pneumococcal Vaccine. Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, October 2016. Available at https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian National Advisory Committee on Immunization (NACI) 2016. https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Croxtall JD and Keating GM, &ldquo;Pneumococcal Polysaccharide Protein D-Conjugate Vaccine (Synflorix&trade;; PHiD-CV),&rdquo; <i>Pediatr Drugs</i>, 2009, 11(5):349-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-10-valent-united-states-not-available-drug-information/abstract-text/19725600/pubmed\" target=\"_blank\" id=\"19725600\">19725600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-10-valent-united-states-not-available-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-10-valent-united-states-not-available-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synflorix pneumococcal conjugate vaccine [Non-typeable <i>Haemophilus influenzae</i> (NTHi) protein <i>D, </i>diphtheria or tetanus toxoid conjugates] adsorbed [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; September 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17136 Version 62.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13739550\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13739552\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13739609\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22457653\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22457654\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13739639\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F13739638\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13739633\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13739554\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13739549\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13739579\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13739557\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13739558\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13769083\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13769081\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13739555\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13739556\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13739637\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13739599\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671812\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/17136|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}